Ablative radiotherapy for new primaries leads to improved overall survival (OS) compared with initial lung cancer stereotactic body radiation therapy (SBRT) in inoperable patients, a recent study has shown.
The urine albumin-to-creatinine ratio (uACR) is an easy and reliable method of ruling out proteinuria >500 mg per day among patients with systemic light chain (AL) amyloidosis, performing relatively well against the 24-hour urine protein collection (24hUP) gold standard, a recent study has found.
Neoadjuvant chemoradiation (C-RT) for locally advanced oesophageal cancer (LAEC) results in a higher degree of pathologically tumour regression, a study has shown. Outcomes are better among patients with major tumour regression than those with minimal to poor response.
The three lymph node (LN) staging systems assessed in a recent study—the eighth TNM staging system, lymph node ratio (LNR, ratio between positive and total LN), and a new anatomic-based classification (Choi classification)—show comparable prognostic performance, but LNR-based classification better stratifies patients with resected gastric carcinoma (GC).
Neither the Comprehensive Geriatric Assessment (CGA) tool nor an oncologist’s clinical judgement can reliably predict unfavourable outcomes in a heterogenous population of elderly cancer patients, a recent study reports.
A tailored follow-up programme for frail and vulnerable elderly cancer patients does not appear to particularly improve the comprehensive geriatric assessment in promoting treatment adherence, a recent study has found.
There is a high prevalence of acute gastrointestinal (GI) symptoms associated with coronavirus disease 2019 (COVID-19) in hospitalized cancer patients, which can occur as a presenting symptom without respiratory symptoms, reveals a recent study. In a small subset of patients, such symptoms are severe.
The best available tool for detecting herb–drug interaction is Lexicomp, and the best free alternative is Medscape, suggests a study. However, the sensitivity and performance for detecting herb–drug interaction is far lower than for drug–drug interactions and quite poor overall.
Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.